Fluphenazine — brand name Prolixin in the US (now mostly available as a generic) — was first approved by the FDA in the 1950s. It is a high-potency phenothiazine, which makes its profile something of a hybrid: phenothiazine chemistry like chlorpromazine, but pharmacology much closer to haloperidol. Its long-acting depot form, fluphenazine decanoate, was one of the earliest antipsychotic LAIs and made it possible for many people with schizophrenia to live in the community rather than in long-stay hospitals.
Fluphenazine is a high-potency typical antipsychotic available as both oral tablets and a long-acting injection, useful for adherence support but with a meaningful risk of movement side effects.
How fluphenazine works
Like haloperidol, fluphenazine is primarily a dopamine D2 receptor blocker. Although it is a phenothiazine, its high-potency profile means it has less of the histamine-driven sedation, blood pressure changes, and weight gain seen with chlorpromazine. The trade-off is more EPS — particularly acute dystonia, parkinsonism, and akathisia.
What it treats
Fluphenazine is FDA-approved for:
- Schizophrenia — both acute and maintenance treatment
- Management of psychotic disorders more broadly
Forms and dosing
Three forms are available:
- Oral tablets and elixir — taken once or twice daily
- Fluphenazine hydrochloride short-acting injection — used in acute settings
- Fluphenazine decanoate — the long-acting injection, given roughly every 2 to 4 weeks
Specific dosing depends heavily on whether you are stabilising acutely or maintaining long-term, and is decided with your prescriber. Notably, for the decanoate, there is a rough conversion ratio between the daily oral dose and the depot dose — but this conversion is something prescribers do, not patients.
The decanoate depot
Fluphenazine decanoate was approved in 1972, making it one of the longest-running LAIs on the market. It is dissolved in sesame oil and injected deep into the gluteal muscle, where it slowly releases active drug over 2 to 4 weeks. Because it is so familiar to clinicians, often inexpensive, and effective, it remains a routine option in community mental health clinics worldwide. Newer LAIs (paliperidone, aripiprazole) are usually first-choice for new starts, but fluphenazine decanoate is still chosen frequently when cost is a factor.
Oral overlap and missed-dose protocols
When transitioning from oral to depot fluphenazine, prescribers often continue the oral form during the first weeks while depot levels build up. Missing a depot injection by more than a few days can lead to a gradual fall in blood levels and, eventually, relapse — but the wide window makes the depot more forgiving than oral medication taken once a day. Specific catch-up protocols belong to your prescriber.
Side effects
Movement side effects
Like other high-potency typicals, fluphenazine carries a meaningful EPS risk. The categories are the same as with haloperidol:
- Acute dystonia (sudden painful muscle spasms)
- Parkinsonism (tremor, rigidity, slowed movement)
- Akathisia (internal restlessness, hard to sit still)
- Tardive dyskinesia with long-term exposure
Many patients on fluphenazine are also prescribed an anticholinergic (such as benztropine) to reduce these symptoms — an arrangement that itself has trade-offs (dry mouth, constipation, cognitive slowing).
Other
- Hyperprolactinaemia (irregular periods, breast changes, sexual dysfunction)
- QT prolongation on the ECG
- Mild to moderate sedation, less than chlorpromazine
- Photosensitivity
- Modest metabolic effects (less than most atypicals)
High fever, muscle rigidity, confusion, and unstable vital signs (NMS); painful sustained muscle spasms (acute dystonia); new chest pain or fainting (possible cardiac arrhythmia).
Injection-site reactions
Fluphenazine decanoate is an oily injection. Local reactions are usually mild — a small lump, mild soreness, occasional bruising — but persistent painful nodules or signs of infection should be reported. Switching the injection between left and right gluteal sides at each visit reduces local irritation.
Where fluphenazine fits today
- Patients who have responded well to it historically
- Patients needing an LAI when newer LAIs are unavailable or unaffordable
- Settings with reliable access to depot administration and EPS monitoring
Where it may not fit
- First-episode patients (newer drugs preferred to limit lifetime EPS exposure)
- People with prior severe EPS or tardive dyskinesia
- Older adults with dementia (boxed warning, like all antipsychotics)
Bottom line
Fluphenazine has lost ground to newer LAIs — but it is still a serious option, with decades of evidence behind it. For patients who tolerate it well, who have a stable depot routine, and who value a low-cost, well-understood medication, it can quietly do excellent work. Whether it is the right fit for you is a conversation with your prescriber.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.